Evidence map›Paper›PMID 36070626›Full record

ArticleVirology2022

Vaccination with human alphapapillomavirus-derived L2 multimer protects against human betapapillomavirus challenge, including in epidermodysplasia verruciformis model mice.

Pola Olczak, Margaret Wong, Hua-Ling Tsai, Hao Wang, Reinhard Kirnbauer, Andrew J Griffith, Paul F Lambert, Richard Roden

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Virology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Deficiency inJournal of virology · 2024
    Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Pola OlczakDepartment of Pathology, Johns Hopkins University, 1550 Orleans St, Baltimore, MD, 21287, United States.
Margaret WongDepartment of Pathology, Johns Hopkins University, 1550 Orleans St, Baltimore, MD, 21287, United States.
Hua-Ling TsaiDepartment of Biostatistics, Johns Hopkins University, 550 N Broadway, Baltimore, MD, 21205, United States.
Hao WangDepartment of Biostatistics, Johns Hopkins University, 550 N Broadway, Baltimore, MD, 21205, United States.
Reinhard KirnbauerDepartment of Dermatology, Medical University of Vienna, 1090, Vienna, Austria.
Andrew J GriffithDepartment of Otolaryngology Head-Neck Surgery, College of Medicine-Memphis, University of Tennessee Health Sciences Center, 910 Madison Ave, Memphis, TN, 38163, United States.
Paul F LambertMcArdle Laboratory for Cancer Research, University of Wisconsin-Madison, 1111 Highland Avenue, Madison, WI, 53705, United States.
Richard RodenDepartment of Pathology, Johns Hopkins University, 1550 Orleans St, Baltimore, MD, 21287, United States. Electronic address: roden@jhmi.edu.
Johns Hopkins University · USMedical University of Vienna · ATUniversity of Tennessee Health Science Center · USUniversity of Wisconsin–Madison · US

Funding

Translational Research Central ServicesP30CA006973 · NCI · JOHNS HOPKINS UNIVERSITY · PI ALAN KEITH MEEKER · 1985 to 2026
$208.6M
Treatment of HIV- and HIV+ Patients with HPV16+ CIN2/3 Using pNGLV4a-hCRTE6E7L2 DNA vaccine administered intramuscularly via electroporationP50CA098252 · NCI · JOHNS HOPKINS UNIVERSITY · PI WARNER KING HUH, TZYY-CHOOU WU · 2003 to 2026
$53.5M
Defining Drivers of HPV-associated CarcinogenesisR35CA210807 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI Paul F. Lambert · 2017 to 2026
$9.2M
Mouse modeling of HPV infectionR01CA233486 · NCI · JOHNS HOPKINS UNIVERSITY · PI HUNG, CHIEN-FU, RODEN, RICHARD BRUCE · 2019 to 2023
$3.0M
Development of Novel Spontaneous HPV Cervicovaginal Carcinoma Models for Cancer ImmunotherapyR01CA237067 · NCI · JOHNS HOPKINS UNIVERSITY · PI WU, TZYY-CHOOU · 2019 to 2023
$2.9M
NCI NIH HHS P30 CA006973NCI NIH HHS P50 CA098252NCI NIH HHS R01 CA233486NCI NIH HHS R01 CA237067NCI NIH HHS R35 CA210807
6 · The paper itself

Abstract

Human alphapapillomaviruses (αHPV) infect genital mucosa, and a high-risk subset is a necessary cause of cervical cancer. Licensed L1 virus-like particle (VLP) vaccines offer immunity against the nine most common αHPV associated with cervical cancer and genital warts. However, vaccination with an αHPV L2-based multimer vaccine, α11-88x5, protected mice and rabbits from vaginal and skin challenge with diverse αHPV types. While generally clinically inapparent, human betapapillomaviruses (βHPV) are possibly associated with cutaneous squamous cell carcinoma (CSCC) in epidermodysplasia verruciformis (EV) and immunocompromised patients. Here we show that α11-88x5 vaccination protected wild type and EV model mice against HPV5 challenge. Passive transfer of antiserum conferred protection independently of Fc receptors (FcR) or Gr-1+ phagocytes. Antisera demonstrated robust antibody titers against ten βHPV by L1/L2 VLP ELISA and neutralized and protected against challenge by 3 additional βHPV (HPV49/76/96). Thus, unlike the licensed vaccines, α11-88x5 vaccination elicits broad immunity against αHPV and βHPV.

Indexed as

AlphapapillomavirusBetapapillomavirusCarcinoma, Squamous CellEpidermodysplasia VerruciformisPapillomavirus InfectionsPapillomavirus VaccinesSkin NeoplasmsUterine Cervical NeoplasmsVaccines, Virus-Like ParticleAnimalsCapsid ProteinsFemaleHumansImmune SeraMiceRabbitsCapsid ProteinsImmune SeraPapillomavirus VaccinesReceptors, FcVaccines, Virus-Like ParticleCutaneous squamous cell carcinomaEpidermodysplasia verruciformisFc receptorHPVHuman papillomavirusesL1 capsid proteinL2 capsid proteinMultimerPreventive vaccinationVirus-like particle

Identifiers

PMID36070626
PMCPMC9710205
OpenAlexW4292737279

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.